Trends in breast, colon, pancreatic, and uterine cancers in women during the COVID‐19 pandemic in North Carolina
Cancer Medicine · 2024
DOI: 10.1002/cam4.7156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Sarah J Nyante und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: COVID-19, Breast Neoplasms, Uterine Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Importance The COVID‐19 pandemic led to reductions in primary care and cancer screening visits, which may delay detection of some cancers. The impact on incidence has not been fully quantified. We examined change in cancer incidence to determine how the COVID‐19 pandemic may have altered the characteristics of cancers diagnosed among women.
Methods
This study included female patients aged ≥18 years and diagnosed with breast ( n = 9489), colon ( n = 958), pancreatic ( n = 669), or uterine ( n = 1991) cancer at three hospitals in North Carolina. Using interrupted time series, we compared incidence of cancers diagnosed between March 2020 and November 2020 (during pandemic) with cancers diagnosed between January 2016 and February 2020 (pre‐pandemic).
Results
During the pandemic, incidence of breast and uterine cancers was significantly lower than expected compared to pre‐pandemic (breast—18%, p = 0.03; uterine −20%, p = 0.05). Proportions of advanced pathologic stage and hormone receptor‐negative breast cancers, and advanced clinical stage and large size uterine cancers were more prevalent during the pandemic. No significant changes in incidence were detected for pancreatic (−20%, p = 0.08) or colon (+14%, p = 0.30) cancers. Conclusion and Relevance In women, the COVID‐19 pandemic resulted in a significant reduction in the incidence of breast and uterine cancers, but not colon or pancreatic cancers. A change in the proportion of poor prognosis breast and uterine cancers suggests that some cancers that otherwise would have been diagnosed at an earlier stage will be detected in later years. Continued analysis of long‐term trends is needed to understand the full impact of the pandemic on cancer incidence and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Sarah J Nyante, Benjamin C Calhoun
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- National Cancer Institute
- National Center for Advancing Translational Sciences
Zitieren
APA
Nyante, S. J., Deal, A. M., Heiling, H. M., Kim, K. S., Kuzmiak, C. M., Calhoun, B. C., & Ray, E. M. (2024). Trends in breast, colon, pancreatic, and uterine cancers in women during the COVID‐19 pandemic in North Carolina. Cancer Medicine. https://doi.org/10.1002/cam4.7156
Vancouver
Nyante SJ, Deal AM, Heiling HM, Kim KS, Kuzmiak CM, Calhoun BC, et al. Trends in breast, colon, pancreatic, and uterine cancers in women during the COVID‐19 pandemic in North Carolina. Cancer Medicine. 2024. doi:10.1002/cam4.7156
BibTeX
@article{Nyante2024,
author = {Nyante, Sarah J and Deal, Allison M and Heiling, Hillary M and Kim, Kyung Su and Kuzmiak, Cherie M and Calhoun, Benjamin C and Ray, Emily M},
title = {Trends in breast, colon, pancreatic, and uterine cancers in women during the COVID‐19 pandemic in North Carolina},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7156}
}
EUVIMED